cacy in polymicrobial infections such as obstetric, gynecologic, and soft-tissue infections. Piperacillin/ tazobactam appears to be an appropriate drug for the empiric treatment of gynecologic infections because of its broad spectrum, good penetration of tissues, and minimal side-effect profile. Multiple studies have demonstrated that piperacillin/tazobactam, compared with "gold standard" treatment regimens, is an equally effective and safe alternative. It may also prove to be more cost effective, based on early reports of broad microbiologic coverage and high cure rates.
STRUCTURE AND DERIVATION
Piperacillin is a semisynthetic ureidopenicillin with an extended spectrum of activity. Piperacillin sodium is derived from D(-)-ot-aminobenzylpenicillin. The chemical name is sodium (2S, 5R, 6R)-6-[(R)-2-(4-ethyl-2,3-d oxo-p perazi n e-car boxyamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-l-azabicyclo [3.2.1]-heptane-2-carboxylate.
Tazobactam sodium is a triazolymethyl penicillanic-acid sulfone derivative. The triazole ring facilitates the binding of tazobactam to [3- [3- lactam inhibitors in that it exhibits minimal induction of class-l, chromosomally mediated 13-1acta-mase enzymes. 
